Literature DB >> 23821278

In vivo evaluation of antiviral efficacy against genital herpes using mouse and guinea pig models.

Frances Valencia1, Ronald L Veselenak, Nigel Bourne.   

Abstract

Both the guinea pig and mouse are important animal models for the study of genital herpes. The murine model has been used extensively to evaluate vaccines and antiviral agents by measuring the incidence of infection and the magnitude of viral replication; however, this model is limited with regard to distinguishing between candidate vaccines or treatments. In contrast, the guinea pig closely mimics human infection and provides an excellent model of both primary and recurrent genital herpes disease. This animal model is especially important in the study of viral transmission through the evaluation of latent viral reactivation and virus shedding into the genital tract. Here, we describe methodologies to determine viral infection, severity of primary disease, and quantification of primary viral replication in the genital tract for both the guinea pig and murine models of genital herpes. Additionally, we detail the evaluation of the onset of primary disease and progression to the day of death in the mouse model. Further, we summarize methods to assess the frequency of recurrences, frequency and magnitude of virus shedding, and latent viral load in the sensory nerve ganglia of the guinea pig.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23821278     DOI: 10.1007/978-1-62703-484-5_24

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  11 in total

1.  Development of an anti-guinea pig CD4 monoclonal antibody for depletion of CD4+ T cells in vivo.

Authors:  Brianne N Banasik; Clarice L Perry; Celeste A Keith; Nigel Bourne; Hubert Schäfer; Gregg N Milligan
Journal:  J Immunol Methods       Date:  2019-08-14       Impact factor: 2.303

2.  Development of disease and immunity at the genital epithelium following intrarectal inoculation of male guinea pigs with herpes simplex virus type 2.

Authors:  Nigel Bourne; Brianne N Banasik; Clarice L Perry; Aaron L Miller; Mellodee White; Richard B Pyles; Gregg N Milligan
Journal:  Virology       Date:  2018-11-06       Impact factor: 3.616

3.  Increased Frequency of Virus Shedding by Herpes Simplex Virus 2-Infected Guinea Pigs in the Absence of CD4+ T Lymphocytes.

Authors:  Nigel Bourne; Clarice L Perry; Brianne N Banasik; Aaron L Miller; Mellodee White; Richard B Pyles; Hubert Schäfer; Gregg N Milligan
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

Review 4.  Animal models of herpes simplex virus immunity and pathogenesis.

Authors:  Christina M Kollias; Richard B Huneke; Brian Wigdahl; Stephen R Jennings
Journal:  J Neurovirol       Date:  2014-11-12       Impact factor: 2.643

5.  Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.

Authors:  Gita N Shankar; Carsten Alt
Journal:  J Antimicrob Chemother       Date:  2014-08-19       Impact factor: 5.790

6.  Detection of herpes simplex virus type 2 (HSV-2) -specific cell-mediated immune responses in guinea pigs during latent HSV-2 genital infection.

Authors:  Clarice L Perry; Brianne N Banasik; Summer R Gorder; Jingya Xia; Sarah Auclair; Nigel Bourne; Gregg N Milligan
Journal:  J Immunol Methods       Date:  2016-09-19       Impact factor: 2.303

7.  Transcriptional Analysis of the Guinea Pig Mucosal Immune Response to Intravaginal Infection with Herpes Simplex Virus Type 2.

Authors:  Ronald L Veselenak; Gregg N Milligan; Aaron L Miller; Richard B Pyles; Nigel Bourne
Journal:  Virology       Date:  2018-03-28       Impact factor: 3.616

Review 8.  Prospects and perspectives for development of a vaccine against herpes simplex virus infections.

Authors:  Shane C McAllister; Mark R Schleiss
Journal:  Expert Rev Vaccines       Date:  2014-07-31       Impact factor: 5.217

9.  Virus-specific immune memory at peripheral sites of herpes simplex virus type 2 (HSV-2) infection in guinea pigs.

Authors:  Jingya Xia; Ronald L Veselenak; Summer R Gorder; Nigel Bourne; Gregg N Milligan
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

Review 10.  Natural Products-Derived Chemicals: Breaking Barriers to Novel Anti-HSV Drug Development.

Authors:  Jakub Treml; Markéta Gazdová; Karel Šmejkal; Miroslava Šudomová; Peter Kubatka; Sherif T S Hassan
Journal:  Viruses       Date:  2020-01-29       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.